

RECORDATI: PROPOSAL OF CANDIDATES FOR THE OFFICE OF DIRECTORS AND THEIR RELATIVE REMUNERATION PRESENTED BY THE MAJORITY SHAREHOLDER FIMEI S.p.A. IN RELATION TO ITEM 2 ON THE AGENDA OF THE SHAREHOLDERS' MEETING

Milan, 17th April 2020 – In relation to the Ordinary General Meeting of the Shareholders to be held on 29th April 2020, in a single call, Recordati S.p.A. informs to have received today and made available to the public the proposal of candidates for the office of directors and their relative remuneration presented by the majority shareholder FIMEI S.p.A. (which owns 51.82% of Recordati S.p.A.'s share capital) in relation to Item 2 on the agenda of the Shareholders' Meeting (*Integration of the Board of Directors after first changing the number of its members and related and consequent resolutions*).

The proposal is available to the public on the "1info" storage mechanism (www.1info.it) and on the Company's website (www.recordati.it - section Investors - Shareholders Meetings) jointly with the relevant documentation requested by law and by the Company's By-laws.

***Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.*

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorisemorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale

VIA M. CIVITALI, 1

20148 MILANO, ITALIA

TEL. (39) 0248787.1

FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.

REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150

CODICE FISCALE/P. IVA 00748210150

R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l